170 related articles for article (PubMed ID: 22249693)
21. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
22. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
[TBL] [Abstract][Full Text] [Related]
23. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.
Ghesquières H; Stamatoullas A; Casasnovas O; Morschhauser F; Gyan E; Gabarre J; Malphettes M; Clément L; Ferlay C; Brice P
Leuk Lymphoma; 2013 Nov; 54(11):2399-404. PubMed ID: 23410099
[TBL] [Abstract][Full Text] [Related]
24. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
25. Bendamustine.
Balfour JA; Goa KL
Drugs; 2001; 61(5):631-8; discussion 639-40. PubMed ID: 11368287
[TBL] [Abstract][Full Text] [Related]
26. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
27. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.
Visani G; Stefani PM; Capria S; Malerba L; Galieni P; Gaudio F; Specchia G; Meloni G; Gherlinzoni F; Gonella R; Gobbi M; Santoro A; Ferrara F; Rocchi M; Ocio EM; Caballero MD; Loscocco F; Isidori A
Blood; 2014 Nov; 124(19):3029-31. PubMed ID: 25377565
[No Abstract] [Full Text] [Related]
28. A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma.
Warsch S; Hosein PJ; Maeda LS; Alizadeh AA; Lossos IS
Leuk Lymphoma; 2012 Jul; 53(7):1299-1305. PubMed ID: 22185662
[TBL] [Abstract][Full Text] [Related]
29. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
[TBL] [Abstract][Full Text] [Related]
30. Bendamustine therapy in chronic lymphocytic leukemia.
Masiello D; Tulpule A
Expert Opin Pharmacother; 2009 Jul; 10(10):1687-98. PubMed ID: 19527193
[TBL] [Abstract][Full Text] [Related]
31. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Chamberlain MC; Colman H; Kim BT; Raizer J
J Neurooncol; 2017 Feb; 131(3):507-516. PubMed ID: 28204914
[TBL] [Abstract][Full Text] [Related]
32. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
[TBL] [Abstract][Full Text] [Related]
33. Bendamustine: a bridge to longer term solutions in heavily treated Hodgkin lymphoma.
Moskowitz A
Leuk Lymphoma; 2013 Nov; 54(11):2339-40. PubMed ID: 24093891
[No Abstract] [Full Text] [Related]
34. Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.
Darwish M; Megason G; Bond M; Hellriegel E; Robertson P; Grasela T; Phillips L
Curr Med Res Opin; 2014 Nov; 30(11):2305-15. PubMed ID: 25105914
[TBL] [Abstract][Full Text] [Related]
35. Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine.
Hui M; Chen M
Ann Hematol; 2022 Apr; 101(4):911-913. PubMed ID: 34487230
[No Abstract] [Full Text] [Related]
36. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
37. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Ujjani C; Cheson BD
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
[TBL] [Abstract][Full Text] [Related]
38. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
39. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.
Kahl BS; Bartlett NL; Leonard JP; Chen L; Ganjoo K; Williams ME; Czuczman MS; Robinson KS; Joyce R; van der Jagt RH; Cheson BD
Cancer; 2010 Jan; 116(1):106-14. PubMed ID: 19890959
[TBL] [Abstract][Full Text] [Related]
40. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.
Owen JS; Melhem M; Passarell JA; D'Andrea D; Darwish M; Kahl B
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1039-49. PubMed ID: 20140617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
